Flu-Bu-Mel Based Conditioning Regimen for Patients With Lymphoid Malignancies Undergoing Allo-HSCT

Phase II Clinical Trial of Flu-Bu-Mel-E (Fludarabine, Busulfan, Melphalan and Etoposide) as Conditioning Regimen for Patients With Lymphoid Malignancies Undergoing Allogeneic Stem Cell Transplantation

In this phase II clinical trial, we evaluate the efficacy and feasibility of conditioning regimen of fludarabine 150mg/m2, busulfan 9.6mg/kg, melphalan 100mg/m2 and etoposide 800mg/m2 in patients with lymphoid malignancies.

Inclusion Criteria:

• lymphoid malignancies
• donor available: HLA matched sibling, unrelated donor or haplo-identical related donor.
• patients with ECOG <3

Exclusion Criteria:

• inform consent not provided
• ECOG >=3
• poor liver function (enzyme >2N or bilirubin >2N)
• poor renal function (Scr >2N)
• poor cardiac function (EF <45%)